La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

KPC PharmaceuticalsInc Gestion

Gestion contrôle des critères 0/4

We currently do not have sufficient information about the CEO.

Informations clés

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	no data
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	pas de données
Durée moyenne du mandat des membres du conseil d'administration	2.7yrs

Mises à jour récentes de la gestion

Recent updates

KPC PharmaceuticalsInc (SHSE:600422) Will Pay A Larger Dividend Than Last Year At CN¥0.20

Jul 25

Investors Still Waiting For A Pull Back In KPC Pharmaceuticals,Inc (SHSE:600422)

Jun 25

We Think KPC PharmaceuticalsInc (SHSE:600422) Can Stay On Top Of Its Debt

Jun 04

KPC PharmaceuticalsInc's (SHSE:600422) Profits May Not Reveal Underlying Issues

Mar 28

PDG

KPC PharmaceuticalsInc n'a pas de PDG, ou nous n'avons pas de données sur eux.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Ting Guo	Director	1.6yrs	pas de données	pas de données
Hui Zhou	Director	less than a year	pas de données	pas de données
Huawei Qiu	Chairman	1.6yrs	pas de données	pas de données
Jin Guo Xin	Independent Director	2.7yrs	CN¥100.00k	pas de données
Ke Liu	Independent Director	5.8yrs	CN¥100.00k	pas de données
Zheng Liang	Director	1.6yrs	pas de données	pas de données
Li Lin Xi	Employee Supervisor	5.8yrs	pas de données	pas de données
Zhang Weng Sen	Employee Supervisor	5.8yrs	pas de données	pas de données
Hongshen Li	Vice Chairman	less than a year	pas de données	pas de données
Zhi Yang	Independent Director	2.7yrs	CN¥100.00k	pas de données
Kang Deng	Supervisor	3.3yrs	pas de données	pas de données

2.7yrs

Durée moyenne de l'emploi

52yo

Âge moyen

Conseil d'administration expérimenté: 600422's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.

KPC PharmaceuticalsInc Gestion

Gestion contrôle des critères 0/4

Informations clés

Mises à jour récentes de la gestion

KPC Pharmaceuticals,Inc, Annual General Meeting, Jun 21, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Investor sentiment deteriorates as stock falls 16%

KPC PharmaceuticalsInc (SHSE:600422) Will Pay A Larger Dividend Than Last Year At CN¥0.20

Dividend increased to CN¥0.20

KPC Pharmaceuticals,Inc. to Report First Half, 2024 Results on Aug 23, 2024

Investors Still Waiting For A Pull Back In KPC Pharmaceuticals,Inc (SHSE:600422)

We Think KPC PharmaceuticalsInc (SHSE:600422) Can Stay On Top Of Its Debt

KPC Pharmaceuticals,Inc, Annual General Meeting, Jun 21, 2024

Price target decreased by 7.1% to CN¥25.01

KPC Pharmaceuticals,Inc to Report Q1, 2024 Results on Apr 27, 2024

KPC PharmaceuticalsInc's (SHSE:600422) Profits May Not Reveal Underlying Issues

Full year 2023 earnings: EPS and revenues miss analyst expectations

KPC Pharmaceuticals,Inc to Report Fiscal Year 2023 Results on Mar 22, 2024

Third quarter 2023 earnings released

Investor sentiment improves as stock rises 16%

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.14 in 2Q 2022)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment deteriorates as stock falls 16%

KPC Pharmaceuticals,Inc to Report First Half, 2023 Results on Aug 30, 2023

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 15%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.21 (vs CN¥0.13 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.18 in 2Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.17 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.17 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.12 in 1Q 2020)

New Hope Healthcare Nanjing Investment Center (Limited Partnership) signed an agreement to acquire 3.7% stake in Nanjing Weili Zhibo Biotechnology Co., Ltd. from KPC Pharmaceuticals, Inc. (SHSE:600422) for CNY 30 million.

Full year 2020 earnings released: EPS CN¥0.60 (vs CN¥0.60 in FY 2019)

New 90-day low: CN¥8.34

KPC Pharmaceuticals, Inc. to Report Fiscal Year 2020 Results on Mar 16, 2021

New 90-day low: CN¥8.38

New 90-day low: CN¥9.12

New 90-day low: CN¥9.54

Third quarter earnings released

KPC Pharmaceuticals, Inc. to Report Q3, 2020 Results on Oct 22, 2020

A group of buyers agreed to acquire 51% stake in Kunming Yinnuo Pharmaceutical Technology Co., Ltd. from KPC Pharmaceuticals, Inc. (SHSE:600422) for approximately CNY 170 million.

KPC Pharmaceuticals, Inc. (SHSE:600422) cancelled the acquisition of 30% stake in Zhejiang Holley Nanhu Pharmaceutical Co., Ltd.

First half earnings released

New 90-day high - CN¥11.67

KPC Pharmaceuticals, Inc. to Report First Half, 2020 Results on Aug 21, 2020

PDG

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen